We are live on ! Find out more
BMY icon

Bristol-Myers Squibb

2,481 hedge funds and large institutions have $102B invested in Bristol-Myers Squibb in 2023 Q2 according to their latest regulatory filings, with 126 funds opening new positions, 947 increasing their positions, 1,065 reducing their positions, and 163 closing their positions.

New
Increased
Maintained
Reduced
Closed

43% more call options, than puts

Call options by funds: $1.43B | Put options by funds: $995M

0.44% less ownership

Funds ownership: 76.44%76% (-0.44%)

2% less funds holding

Funds holding: 2,5412,481 (-60)

8% less capital invested

Capital invested by funds: $111B → $102B (-$8.64B)

11% less repeat investments, than reductions

Existing positions increased: 947 | Existing positions reduced: 1,065

23% less first-time investments, than exits

New positions opened: 126 | Existing positions closed: 163

35% less funds holding in top 10

Funds holding in top 10: 6844 (-24)

Holders
2,481
Holders Change
-60
Holders Change %
-2.36%
% of All Funds
38.95%
Holding in Top 10
44
Holding in Top 10 Change
-24
Holding in Top 10 Change %
-35.29%
% of All Funds
0.69%
New
126
Increased
947
Reduced
1,065
Closed
163
Calls
$1.43B
Puts
$995M
Net Calls
+$431M
Net Calls Change
-$137M
Name Holding Trade Value Shares
Change
Change in
Stake
MSV
151
MN Services Vermogensbeheer
Netherlands
$64.5M -$5.35M -79,800 -7%
Lazard Asset Management
152
Lazard Asset Management
New York
$64.1M +$4.16M +62,108 +7%
Squarepoint
153
Squarepoint
New York
$63.4M +$65.1M +970,996 +4,845%
Handelsbanken Fonder
154
Handelsbanken Fonder
Sweden
$62.7M -$2.92M -43,548 -4%
Natixis Advisors
155
Natixis Advisors
Massachusetts
$62.3M +$3.17M +47,253 +5%
EIP
156
Epoch Investment Partners
New York
$61.8M +$31.8M +474,907 +97%
Aviva
157
Aviva
United Kingdom
$61.3M +$13.1M +195,646 +26%
KBG
158
Kahn Brothers Group
New York
$61.3M -$1.97M -29,312 -3%
RCM
159
RNC Capital Management
California
$59.7M -$1.74M -25,960 -3%
Rockefeller Capital Management
160
Rockefeller Capital Management
New York
$59.4M +$2.43M +36,294 +4%
HA
161
Homestead Advisers
Virginia
$59.2M +$302K +4,500 +0.5%
Balyasny Asset Management
162
Balyasny Asset Management
Illinois
$57M +$19.3M +288,296 +48%
FPCG
163
Fort Pitt Capital Group
Pennsylvania
$56.3M +$1.6M +23,919 +3%
AT
164
AMF Tjänstepension
Sweden
$56.2M
HPC
165
HM Payson & Co
Maine
$55.5M -$16.5M -246,133 -22%
Nomura Asset Management
166
Nomura Asset Management
Japan
$54.4M +$2.41M +35,937 +4%
LCM
167
Laurion Capital Management
New York
$53.9M +$56.6M +843,329 New
SG Americas Securities
168
SG Americas Securities
New York
$53.8M +$22.8M +340,741 +68%
PI
169
PFS Investments
Georgia
$52.4M +$2.61M +38,938 +5%
ERSOT
170
Employees Retirement System of Texas
Texas
$51.9M +$6.75M +100,600 +14%
CSS
171
Cubist Systematic Strategies
Connecticut
$50.7M +$46.5M +694,069 +700%
HPG
172
Harvest Portfolios Group
Ontario, Canada
$49.3M +$4.38M +65,324 +9%
Janney Montgomery Scott
173
Janney Montgomery Scott
Pennsylvania
$48.8M +$495K +7,382 +1%
RJFSA
174
Raymond James Financial Services Advisors
Florida
$48.7M -$5.81M -86,706 -10%
AI
175
Ariel Investments
Illinois
$48.7M -$1.69M -25,255 -3%

BMY Hedge Fund Activity: Q2 2023 in Review

2,481 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Bristol-Myers Squibb (BMY) for Q2 2023, worth a combined $102B — down 7.8% from $111B a quarter earlier.

Sellers outnumbered buyers: 163 funds closed out of BMY and 126 opened new positions — a net loss of 37 holders — while 1,065 trimmed existing stakes and 947 added.

The largest buyer was Capital International Investors, adding an estimated $528M. The largest seller was Bank of America, cutting an estimated $634M.

  • 2,481 institutional investors held Bristol-Myers Squibb (BMY) as of Q2 2023, down from 2,541 in Q1 2023.
  • Funds reported $102B of Bristol-Myers Squibb stock for Q2 2023, down 7.8% quarter-over-quarter.
  • 126 funds opened new Bristol-Myers Squibb positions in Q2 2023 and 163 closed out, a net change of -37 holders.
  • The largest Bristol-Myers Squibb buyer in Q2 2023 was Capital International Investors, an estimated $528M added.
  • The largest Bristol-Myers Squibb seller in Q2 2023 was Bank of America, an estimated $634M sold.

Based on aggregated 13F filings for Q2 2023.